Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Artigo em Inglês | MEDLINE | ID: mdl-38465885

RESUMO

BACKGROUND: Foslevodopa/foscarbidopa is a subcutaneous infusion of levodopa/carbidopa prodrugs. OBJECTIVES: Assess correlations between sleep and efficacy from interim data of a phase 3 trial of foslevodopa/foscarbidopa (NCT03781167). METHODS: Pearson correlations between sleep (Parkinson's Disease Sleep Scale-2 [PDSS-2]) and quality of life (QoL; Parkinson's Disease Questionnaire-39), motor experiences of daily living (m-EDL; Movement Disorder Society-Unified Parkinson's Disease Scale Part II), and "Off"/"On" times were calculated for baseline and week 26 improvements. Regression analyses were adjusted for baseline PDSS-2 score. RESULTS: Baseline sleep correlated moderately with QoL (r = 0.44, P < 0.001) and weakly with m-EDL (r = 0.28; P < 0.001). Sleep improvement weakly correlated with improved "Off" time (r = 0.37; P < 0.001) and QoL (r = 0.36; P < 0.001). Regression analyses demonstrated significant positive associations for improved sleep, "Off" time, QoL, and m-EDL. CONCLUSIONS: Improved sleep with foslevodopa/foscarbidopa was associated with improved QoL and "Off" time.

2.
Clin Park Relat Disord ; 10: 100239, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38419617

RESUMO

Background: As Parkinson's disease (PD) advances, management is challenged by an increasingly variable and inconsistent response to oral dopaminergic therapy, requiring special considerations by the provider. Continuous 24 h/day subcutaneous infusion of foslevodopa/foscarbidopa (LDp/CDp) provides steady dopaminergic stimulation that can reduce symptom fluctuation. Objective: Our aim is to review the initiation, optimization, and maintenance of LDp/CDp therapy, identify possible challenges, and share potential mitigations. Methods: Review available LDp/CDp clinical trial data for practical considerations regarding the management of patients during LDp/CDp therapy initiation, optimization, and maintenance based on investigator clinical trial experience. Results: LDp/CDp initiation, optimization, and maintenance can be done without hospitalization in the clinic setting. Continuous 24 h/day LDp/CDp infusion can offer more precise symptom control than oral medications, showing improvements in motor fluctuations during both daytime and nighttime hours. Challenges include infusion-site adverse events for which early detection and prompt management may be required, as well as systemic adverse events (eg, hallucinations) that may require adjustment of the infusion rate or other interventions. A learning curve should be anticipated with initiation of therapy, and expectation setting with patients and care partners is key to successful initiation and maintenance of therapy. Conclusion: Continuous subcutaneous infusion of LDp/CDp represents a promising therapeutic option for individuals with PD. Individualized dose optimization during both daytime and nighttime hours, coupled with patient education, and early recognition of certain adverse events (plus their appropriate management) are required for the success of this minimally invasive and highly efficacious therapy.

4.
Neurol Ther ; 12(6): 1937-1958, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37632656

RESUMO

INTRODUCTION: Foslevodopa/foscarbidopa, a soluble formulation of levodopa/carbidopa (LD/CD) prodrugs for the treatment of Parkinson's disease (PD), is administered as a 24-hour/day continuous subcutaneous infusion (CSCI) with a single infusion site. The efficacy and safety of foslevodopa/foscarbidopa versus oral immediate-release LD/CD was previously demonstrated in patients with PD in a 12-week, randomized, double-blind, phase 3 trial (NCT04380142). We report the results of a separate 52-week, open-label, phase 3 registrational trial (NCT03781167) that evaluated the safety/tolerability and efficacy of 24-hour/day foslevodopa/foscarbidopa CSCI in patients with advanced PD. METHODS: Male and female patients with levodopa-responsive PD and ≥ 2.5 hours of "Off" time/day received 24-hour/day foslevodopa/foscarbidopa CSCI at individually optimized therapeutic doses (approximately 700-4250 mg of LD per 24 hours) for 52 weeks. The primary endpoint was safety/tolerability. Secondary endpoints included changes from baseline in normalized "Off" and "On" time, percentage of patients reporting morning akinesia, Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Parkinson's Disease Sleep Scale-2 (PDSS-2), 39-item Parkinson's Disease Questionnaire (PDQ-39), and EuroQol 5-dimension questionnaire (EQ-5D-5L). RESULTS: Of 244 enrolled patients, 107 discontinued, and 137 completed treatment. Infusion site events were the most common adverse events (AEs). AEs were mostly nonserious (25.8% of patients reported serious AEs) and mild/moderate in severity. At week 52, "On" time without troublesome dyskinesia and "Off" time were improved from baseline (mean [standard deviation (SD)] change in normalized "On" time without troublesome dyskinesia, 3.8 [3.3] hours; normalized "Off" time, -3.5 [3.1] hours). The percentage of patients experiencing morning akinesia dropped from 77.7% at baseline to 27.8% at week 52. Sleep quality (PDSS-2) and quality of life (PDQ-39 and EQ-5D-5L) also improved. CONCLUSION: Foslevodopa/foscarbidopa has the potential to provide a safe and efficacious, individualized, 24-hour/day, nonsurgical alternative for patients with PD. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier NCT03781167.

5.
Learn Mem ; 21(10): 569-74, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25227252

RESUMO

Epigenetic modifications of chromatin structure provide a mechanistic interface for gene-environment interactions that impact the individualization of health trajectories across the lifespan. A growing body of research indicates that dysfunctional epigenetic regulation contributes to poor cognitive outcomes among aged populations. Here we review neuroepigenetic research as it relates to cognitive aging, focusing specifically on memory function mediated by the hippocampal system. Recent work that differentiates epigenetic contributions to chronological aging from influences on mindspan, or the preservation of normal cognitive abilities across the lifespan, is also highlighted. Together, current evidence indicates that while age-related memory impairment is associated with dysfunction in the coordinated regulation of chromatin modification, animal models that show individual differences in cognitive outcome underscore the enormous mechanistic complexity that surrounds epigenetic dynamics in the aged hippocampus.


Assuntos
Envelhecimento/genética , Cognição/fisiologia , Epigênese Genética , Hipocampo/fisiologia , Memória/fisiologia , Animais , Montagem e Desmontagem da Cromatina , Histona Desacetilases/metabolismo , Humanos , Aprendizagem/fisiologia , Camundongos , Plasticidade Neuronal/genética , Ratos
6.
Hippocampus ; 24(11): 1300-7, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24909986

RESUMO

Episodic memory impairment due to aging has been linked to hippocampal dysfunction. Evidence exists for alterations in specific circuits within the hippocampal system that are closely coupled to individual differences in the presence and severity of such memory loss. Here, we used the newly developed Diversity Outbred (DO) mouse that was designed to model the genetic diversity in human populations. Young and aged DO mice were tested in a hippocampal-dependent water maze task. Young mice showed higher proficiency and more robust memory compared to the overall performance of aged mice. A substantial number of the older mice, however, performed on par with the normative performance of the younger mice. Stereological quantification of somatostatin-immunoreactive neurons in the dentate hilus showed that high-performing young and unimpaired aged mice had similar numbers of somatostatin-positive interneurons, while aged mice that were impaired in the spatial task had significantly fewer such neurons. These data in the DO model tie loss of hilar inhibitory network integrity to age-related memory impairment, paralleling data in other rodent models.


Assuntos
Envelhecimento , Cognição/fisiologia , Hipocampo/fisiologia , Animais , Animais não Endogâmicos , Contagem de Células , Sinais (Psicologia) , Hipocampo/patologia , Hipocampo/fisiopatologia , Imuno-Histoquímica , Interneurônios/patologia , Interneurônios/fisiologia , Masculino , Aprendizagem em Labirinto , Transtornos da Memória/patologia , Transtornos da Memória/fisiopatologia , Camundongos , Testes Neuropsicológicos , Fotomicrografia , Somatostatina/metabolismo , Memória Espacial/fisiologia
7.
J Comp Neurol ; 521(15): 3508-23, 2013 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-23749483

RESUMO

Hippocampal interneuron populations are reportedly vulnerable to normal aging. The relationship between interneuron network integrity and age-related memory impairment, however, has not been tested directly. That question was addressed in the present study using a well-characterized model in which outbred, aged, male Long-Evans rats exhibit a spectrum of individual differences in hippocampal-dependent memory. Selected interneuron populations in the hippocampus were visualized for stereological quantification with a panel of immunocytochemical markers, including glutamic acid decarboxylase-67 (GAD67), somatostatin, and neuropeptide Y. The overall pattern of results was that, although the numbers of GAD67- and somatostatin-positive interneurons declined with age across multiple fields of the hippocampus, alterations specifically related to the cognitive outcome of aging were observed exclusively in the hilus of the dentate gyrus. Because the total number of NeuN-immunoreactive hilar neurons was unaffected, the decline observed with other markers likely reflects a loss of target protein rather than neuron death. In support of that interpretation, treatment with the atypical antiepileptic levetiracetam at a low dose shown previously to improve behavioral performance fully restored hilar SOM expression in aged, memory-impaired rats. Age-related decreases in GAD67- and somatostatin-immunoreactive neuron number beyond the hilus were regionally selective and spared the CA1 field of the hippocampus entirely. Together these findings confirm the vulnerability of hippocampal interneurons to normal aging and highlight that the integrity of a specific subpopulation in the hilus is coupled with age-related memory impairment.


Assuntos
Envelhecimento/fisiologia , Hipocampo/patologia , Interneurônios/patologia , Transtornos da Memória/patologia , Animais , Antígenos Nucleares/metabolismo , Comportamento Animal/fisiologia , Região CA3 Hipocampal/citologia , Região CA3 Hipocampal/fisiologia , Contagem de Células , Cognição/fisiologia , Glutamato Descarboxilase/metabolismo , Hipocampo/crescimento & desenvolvimento , Hipocampo/fisiologia , Imageamento Tridimensional , Imuno-Histoquímica , Interneurônios/fisiologia , Levetiracetam , Masculino , Proteínas do Tecido Nervoso/metabolismo , Neuropeptídeo Y/metabolismo , Nootrópicos/farmacologia , Perfusão , Piracetam/análogos & derivados , Piracetam/farmacologia , Ratos , Ratos Long-Evans , Somatostatina/metabolismo
8.
J Comp Neurol ; 520(6): 1318-26, 2012 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-22020730

RESUMO

For many years, aging was thought to be accompanied by significant decreases in total neuron number across multiple brain regions. However, this view was revised with the advent of modern quantification methods, and it is now widely accepted that the hippocampus and many regions of the cortex show substantially preserved numbers of neurons during normal aging. Nonetheless, age-related changes in neuron number do occur in focal regions of the primate prefrontal cortex (PFC), but the question of whether age-related neuron loss is an exclusive characteristic of the PFC in primates remains relatively unexplored. To investigate the loss of neurons with normal aging in rodents, we used unbiased stereological methods to quantify the number of principal neurons and interneurons in the PFC of young and aged rats. We observed a significant age-related decline in the number of principal neurons in the dorsal PFC. The number of interneurons positively stained with antibodies to glutamic acid decarboxylase 67 was also reduced in the dorsal PFC of aged rats. These observations indicate that the dorsal PFC is susceptible to neuron loss with aging in rodent brain and suggest some common basis for vulnerability in cortical circuits across species.


Assuntos
Envelhecimento/patologia , Contagem de Células , Degeneração Neural/patologia , Neurônios/patologia , Córtex Pré-Frontal/patologia , Envelhecimento/fisiologia , Animais , Senescência Celular/fisiologia , Modelos Animais de Doenças , Masculino , Degeneração Neural/fisiopatologia , Neurônios/metabolismo , Córtex Pré-Frontal/fisiopatologia , Ratos , Ratos Long-Evans
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...